CEO Dr. James Bianco provides background to the patent announcement earlier today. He introduces TuHURA’s ADC program and explains how it can address immunosuppressive MDSCs and block the VISTA checkpoint inhibitor.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtu.be/rT1RLh6db8Y
